180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 13,000 shares of the company’s stock, valued at approximately $34,000.
Wall Street Analyst Weigh In
Separately, Raymond James raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, May 22nd.
Read Our Latest Stock Analysis on EPRX
Eupraxia Pharmaceuticals Price Performance
Eupraxia Pharmaceuticals Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- Investing in Construction Stocks
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Why Invest in 5G? How to Invest in 5G Stocks
- Jeff Brown’s Exegesis AI Stock Picks
- Market Cap Calculator: How to Calculate Market Cap
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Want to see what other hedge funds are holding EPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report).
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.